National Vision (EYE)
(Delayed Data from NSDQ)
$13.61 USD
+0.41 (3.11%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $13.61 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.61 USD
+0.41 (3.11%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $13.61 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
Zacks News
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on strong quarterly results and robust pump sales.
National Vision (EYE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 45.45% and 3.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Tandem (TNDM) Global Growth Strong, Costs Continue to Rise
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing high international demand for the t:slim X2 pump.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
Here's Why You Should Buy Amedisys (AMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.
Bull of the Day: National Vision (EYE)
by Kevin Cook
As a nation, optical care needs are rising and re-opening trends are spurring a big catch-up on exams
Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.
Is a Surprise Coming for National Vision (EYE) This Earnings Season?
by Aditi Saraogi
National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to its solid first-quarter performance and impressive value-added acquisitions.
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) backed by its improvement in comparable store sales (comps) in eyeglasses and contact lens.
Medtronic (MDT) to Enhance Patient Care via Digital Portal
by Zacks Equity Research
Medtronic's (MDT) first patient-centric digital health platform is expected to provide better outcome for patients undergoing the company's SCS therapy.
Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.
What's in Store for Asensus Surgical's (ASXC) Q1 Earnings?
by Zacks Equity Research
Asensus Surgical's (ASXC) first-quarter results are likely to reflect benefits from regulatory approvals and collaboration.
National Vision (EYE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) transitions of five additional Walmart Vision Centers in 2020, which have become operative of late, are expected to post positive Q1 results.
Why Is National Vision (EYE) Up 2.2% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.
National Vision (EYE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 246.15% and 5.86%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Rides on Comps Growth Amid COVID-19 Woes
by Zacks Equity Research
National Vision's (EYE) Eyeglass pumps sales are robust driven by increases in both customer transactions and average ticket.
Why Is National Vision (EYE) Down 5.4% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.
National Vision (EYE) Q3 Earnings Surpass Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 107.69% and -1.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?